SCHEMBL14956011

SCHEMBL14956011

CC(=O)N1CCN(c2ccc(Nc3cnc(C(N)=O)c(NC4CC4)n3)cc2)CC1

nearest known ligand 0.67

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 20/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14956008 0.92 SYK (0.65) SYK
SCHEMBL2693903 0.80 SYK (0.73) SYK
SCHEMBL735847 0.80 SYK (1.00) SYK
SCHEMBL16541266 0.80 EML4 (0.70) SYK
SCHEMBL4409414 0.78 SYK (0.67) SYK
SCHEMBL16607702 0.78 SYK (0.94) SYK
SCHEMBL13604962 0.78 SYK (0.87) SYK
SCHEMBL735817 0.77 SYK (1.00) SYK
SCHEMBL735818 0.77 SYK (1.00) SYK
SCHEMBL736954 0.77 SYK (1.00) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9359308-B2 Pyrazine kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2016-06-07 — — US disclosed
US-9359308-B2 Pyrazine kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2016-06-07 — — US disclosed
US-9359308-B2 Pyrazine kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2016-06-07 — — US disclosed
US-8877760-B2 Substituted pyrazine-2-carboxamide kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2014-11-04 — — US disclosed
US-8877760-B2 Substituted pyrazine-2-carboxamide kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2014-11-04 — — US disclosed
US-8877760-B2 Substituted pyrazine-2-carboxamide kinase inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2014-11-04 — — US disclosed
US-20140309209-A1 Pyrazine Kinase Inhibitors ALEXION PHARMACEUTICALS, INC. 2014-10-16 — — US disclosed
US-20140309209-A1 Pyrazine Kinase Inhibitors ALEXION PHARMACEUTICALS, INC. 2014-10-16 — — US disclosed
US-20140309209-A1 Pyrazine Kinase Inhibitors ALEXION PHARMACEUTICALS, INC. 2014-10-16 — — US disclosed
WO-2013078466-A1 PYRAZINE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-30 — — WO disclosed
US-20130131040-A1 PYRAZINE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-23 — — US disclosed
US-20130131040-A1 PYRAZINE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-23 — — US disclosed
US-20130131040-A1 PYRAZINE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131040-A1 PYRAZINE KINASE INHIBITORS SYK, ZAP70, LCK SYK 1/4885
US-20140309209-A1 Pyrazine Kinase Inhibitors SYK, ZAP70, LCK SYK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback